Delphine Remmy, PhD

Delphine Remmy is a Pharm D with a Masters in Public Health from Sciences Po Paris. She has a wealth of experience in clinical research and development, particularly in the field of onco-haematology and has worked as global team leader and director in several different pharmaceutical companies. Delphine returned to Mundipharma EDO in 2017 and is responsible for the conduct of the hematological malignancy clinical trials.

Dan Soltis, PhD

Dan Soltis is a research scientist with over 30 years of experience in the pharmaceutical industry. For the last 20 years his work has focused on the discovery and development of new drugs for the treatment of several different types of cancer. Dr Soltis has a PhD in biophysical chemistry from the University of Illinois with expertise in molecular and cellular biology, biochemistry and tumour biology, including experience with multiple therapeutic approaches including small molecule, antibody, vaccine, gene therapy and siRNA.

Sophie Taillibert, MD

Sophie Taillbert trained as a neuro-oncologist at the Paris V University, France and undertook her Internship and Residency in Neurology at Paris Descartes University. She has worked as a full-time staff physician in the neuro-oncology department of the Salpetriere University Hospital, Paris and as Assistant Professor in the Oncology department of the Pitie Paris VI University Hospital. Dr Taillibert has served as a National Coordinator, Principal Investigator and Co-investigator on a range of Phase I to Phase III studies in neuro-oncology.

Richard Trollope

Nalan Utku MD

Nalân Utku studied medicine in Germany and the USA, spending several years in clinical medicine.
She has over 20 years of experience in preclinical and clinical research, in both academic and commercial environments, and is founder and CEO of CellAct and Professor of Immunology at the Charite Hospital, Berlin. Dr Utku combines outstanding experience and a proven track record in developing therapeutics for oncology and inflammatory diseases from early preclinical to proof of concept clinical stage.

Ines Wagner, PhD

Ines Wagner, PhD brings over 20 years of project and program management experience in various indications from different pharmaceutical companies to the Mundipharma EDO drug development team. During her career, she has held various senior positions in different companies in drug development as well as medical affairs. She graduated from the University of Hamburg in Science and holds an MBA from the German Chamber of Commerce.

Caroline Waldy

Caroline Waldy has over 18 years’ experience in clinical research, working in contract organization (CRO) and pharmaceutical companies. She has worked on drug development in a variety of therapeutics areas, latterly focusing on Oncology, and as a clinical project manager at all stages of drug development, from Phase I studies through to post-registration trials.